CClinicalTrials.gg
CompletedNCT04945083Updated Jan 13, 2022

Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition

An interventional study of Experimental Nutritional Pudding in Gastrointestinal Tolerance, sponsored by Abbott Nutrition. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-13.

Sponsored by Abbott Nutrition · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2021, registered Jun 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, prospective, non-randomized, non-blinded, single-arm, single treatment study to evaluate the tolerance of a nutritional pudding.

02

Conditions studied

  • Gastrointestinal Tolerance

Browse trials for

03

In context

Malnutrition

1,587 studies on the registry are indexed under Malnutrition; 237 are open to participants now.

This study's enrollment of 25 is below the median of 90 across 1,134 interventional studies indexed under Malnutrition.

Browse Malnutrition studies →

Lead sponsor

Abbott Nutrition is the lead sponsor of 153 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject has voluntarily signed and dated an ICF approved by an IEC, and provided applicable privacy authorization prior to any participation
  • Subject is considered by a dietitian or clinician as malnourished or at risk for malnutrition based on current use of an oral nutritional supplement (ONS), recently identified as malnourished or at risk of malnutrition based on validated malnutrition screening tool or has had weight loss within last two months as a result of a hospitalization or chronic illness
  • Subject currently has normal GI function
  • Subject requires ONS and is willing to comply with the study protocol

Exclusion criteria

Exclusion Criteria:

  • Subject has severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder affecting abilities to answer questions, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures
  • Subject had a history of diabetes as evidenced by taking antihyperglycemic medications or by self-reported dietary modification
  • Subject is currently taking or has taken antibiotics within 1 week prior to enrollment
  • Subject has undergone major GI surgery less than 3 months prior to enrollment in the study
  • Subject has current active malignant disease or was treated within the last 6 months for cancer, except basal or squamous cell skin carcinoma, prior to enrollment
  • Subject has an immunodeficiency disorder
  • Subject has had a myocardial infarction within the last 3 months prior to enrollment
  • Subject is known to be allergic or intolerant to any ingredient found in the study product
  • Subject has an aversion to any of the flavours of product being tested
  • Subject has an obstruction of the GI tract precluding ingestion or absorption of the study product, inflammatory bowel disease, gastric esophageal reflux disease, short bowel syndrome, or other major gastrointestinal disease-causing symptoms including (but not limited to) uncontrollable severe diarrhea, nausea, or vomiting
  • Subject is currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or affect gastrointestinal motility
  • Participation in another study that has not been approved as a concomitant study
  • Subject has a clinical condition that is contraindicated with this product as determined by the clinician in accordance with standard of care
  • Subject is pregnant
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Experimental Nutritional Pudding

    2 servings per day

    Other: Experimental Nutritional Pudding

Interventions

  • OtherExperimental Nutritional Pudding

    High Calorie, High Protein pudding

06

What researchers measure

Primary outcomes

  1. Gastro-Intestinal Tolerance

    Subject completed Bristol Stool Type questionnaire; Stool is classified into 7 groups (Types 1-7) with Type 3-4 as ideal stools

    Time frame: Study Day 1 to Study Day 8

Secondary outcomes

  1. Nutritional Supplement Palatability

    Subject completed questionnaire; 4 questions scaled from 1 -Dislike Extremely to 9-Like Extremely; 2 questions scaled from Not at all Enough to Far Too

    Time frame: Study Day 1 to Study Day 8

  2. Nutritional Supplement Compliance

    Subject completed daily intake questionnaire including amount of serving consumed

    Time frame: Study Day 1 to Study Day 28

Other outcomes

  1. Weight

    For BMI Calculation

    Time frame: Baseline to Study Day 28

  2. Height

    For BMI Calculation

    Time frame: Baseline to Study Day 28

  3. Medication Usage

    Subject reported medication usage

    Time frame: Baseline to Study Day 28

  4. Adverse Events

    Subject reported adverse events

    Time frame: Baseline to Study Day 28

07

Study locations

3 sites
  • North Coast Medical Ltd, Newquay Health Centre
    Newquay, Cornwall TR7 1RU, United Kingdom
  • The Alverton Practice, Atlantic Medical
    Penzance, Cornwall TR18 3DX, United Kingdom
  • Morrab Surgery
    Penzance, Cornwall TR18 4EL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04945083
Lead sponsor
Abbott Nutrition
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Jan 13, 2021
Primary completion
Dec 9, 2021
Completion
Dec 9, 2021
Last update
Jan 13, 2022

Study contacts

Maria Camprubi, PhD
study chair · Abbott Nutrition

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion